Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Elite Pharms Inc (OP:ELTP)

0.3896 +0.0015 (+0.39%)
Streaming Delayed Price Updated: 3:52 PM EDT, Mar 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elite Pharms Inc

< Previous 1 2 3 Next >
News headline image
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Northvale, New Jersey--(Newsfile Corp. - June 16, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company... 
Via Newsfile
Topics Intellectual Property
News headline image
Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical... 
Via Newsfile
News headline image
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Via ACCESSWIRE
News headline image
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
News headline image
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)
Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health
Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets
Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company... 
Via Newsfile
News headline image
Top Analyst Reports For Nvidia, American Express & Wells Fargo ↗
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp., American Express Co., and Wells Fargo & Co., as well as two micro-cap stocks Elite Pharmaceuticals, Inc.... 
Via Talk Markets
News headline image
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
ELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q1 2025 ↗
Elite Pharmaceuticals just reported results for the first quarter of 2025. 
Via InvestorPlace
News headline image
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
ELTP Stock Earnings: Elite Pharmaceuticals Reported Results for Q4 2024 ↗
Elite Pharmaceuticals just reported results for the fourth quarter of 2024. 
Via InvestorPlace
News headline image
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
Treasure Hunt: 7 Penny Stocks Wall Street Hasn’t Discovered Yet ↗
Dirt cheap and under-the-radar, there's still time to get in early with each of these seven undiscovered penny stocks. 
Via InvestorPlace
News headline image
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024
Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty... 
Via Newsfile
News headline image
7 Strong Buy Penny Stocks to Buy Now: June 2024 ↗
Each of these low-priced seven strong buy penny stocks could do some real heavy lifting for your portfolio. 
Via InvestorPlace
News headline image
Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate
Via ACCESSWIRE
News headline image
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Via ACCESSWIRE
News headline image
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
Via ACCESSWIRE
News headline image
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
Via ACCESSWIRE
News headline image
Small Stocks, Big Potential: 7 Penny Stocks Poised for Major Gains in 2024 ↗
Wager on these three top penny stocks shining through market uncertainty at this time, poised for a year-end rally. 
Via InvestorPlace
News headline image
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.